Movement Alert｜PegBio Rises 8.37% in Regular Trading, Boosted by HKD 61 Million Commercialization Milestone Payment from Tengrui Pharma

Market Focus06-08

On June 8, PegBio (Peg Bio Pharmaceuticals-B) rose 8.37% in regular trading, trading at HKD 8.4 per share, with trading volume of approximately HKD 93.36 million.

On the news front, the company announced on June 5 that it received the first commercialization milestone payment of HKD 61 million from Shanghai Tengrui Pharmaceutical under their collaboration agreement for Weipeinatide Injection (Paidakang) in mainland China. This payment marks the partnership entering a substantive execution and full-scale advancement phase. Paidakang is the company's proprietary long-acting GLP-1 receptor agonist approved for the treatment of type 2 diabetes.

The stock has been buoyed by multiple positive catalysts in recent sessions, including CR059 research being selected for an oral presentation at the 62nd EASD Annual Meeting, a board proposal to authorize a buyback of up to 10% of issued H shares pending shareholder approval on June 24, and the inclusion of its core product in the national medical insurance reference drug pre-communication supplementary list, strengthening reimbursement access expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141451062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141451062","market":"us","top_or_hot":-1,"title":"Movement Alert｜PegBio Rises 8.37% in Regular Trading, Boosted by HKD 61 Million Commercialization Milestone Payment from Tengrui Pharma","media":"Market Focus","content":"<p><p>On June 8, PegBio (Peg Bio Pharmaceuticals-B) rose 8.37% in regular trading, trading at HKD 8.4 per share, with trading volume of approximately HKD 93.36 million.</p><p>On the news front, the company announced on June 5 that it received the first commercialization milestone payment of HKD 61 million from Shanghai Tengrui Pharmaceutical under their collaboration agreement for Weipeinatide Injection (Paidakang) in mainland China. This payment marks the partnership entering a substantive execution and full-scale advancement phase. Paidakang is the company's proprietary long-acting GLP-1 receptor agonist approved for the treatment of type 2 diabetes.</p><p>The stock has been buoyed by multiple positive catalysts in recent sessions, including CR059 research being selected for an oral presentation at the 62nd EASD Annual Meeting, a board proposal to authorize a buyback of up to 10% of issued H shares pending shareholder approval on June 24, and the inclusion of its core product in the national medical insurance reference drug pre-communication supplementary list, strengthening reimbursement access expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Rises 8.37% in Regular Trading, Boosted by HKD 61 Million Commercialization Milestone Payment from Tengrui Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Rises 8.37% in Regular Trading, Boosted by HKD 61 Million Commercialization Milestone Payment from Tengrui Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-08 10:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 8, PegBio (Peg Bio Pharmaceuticals-B) rose 8.37% in regular trading, trading at HKD 8.4 per share, with trading volume of approximately HKD 93.36 million.</p><p>On the news front, the company announced on June 5 that it received the first commercialization milestone payment of HKD 61 million from Shanghai Tengrui Pharmaceutical under their collaboration agreement for Weipeinatide Injection (Paidakang) in mainland China. This payment marks the partnership entering a substantive execution and full-scale advancement phase. Paidakang is the company's proprietary long-acting GLP-1 receptor agonist approved for the treatment of type 2 diabetes.</p><p>The stock has been buoyed by multiple positive catalysts in recent sessions, including CR059 research being selected for an oral presentation at the 62nd EASD Annual Meeting, a board proposal to authorize a buyback of up to 10% of issued H shares pending shareholder approval on June 24, and the inclusion of its core product in the national medical insurance reference drug pre-communication supplementary list, strengthening reimbursement access expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1141451062","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141451062","pubTimestamp":1780885359,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 8, PegBio (Peg Bio Pharmaceuticals-B) rose 8.37% in regular trading, trading at HKD 8.4 per share, with trading volume of approximately HKD 93.36 million.On the news front, the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"动静|派格生物常规交易涨8.37%，受腾瑞医药6100万港元商业化里程碑付款提振","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On June 8, PegBio (Peg Bio Pharmaceuticals-B) rose 8.37% in regular trading, trading at HKD 8.4 per share, with trading volume of approximately HKD 93.36 million.On the news front, the company announced on June 5 that it received the first commercialization milestone payment of HKD 61 million from Shanghai Tengrui Pharmaceutical under their collaboration agreement for Weipeinatide Injection (Paidakang) in mainland China. This payment marks the partnership entering a substantive execution and full-scale advancement phase. Paidakang is the company's proprietary long-acting GLP-1 receptor agonist approved for the treatment of type 2 diabetes.The stock has been buoyed by multiple positive catalysts in recent sessions, including CR059 research being selected for an oral presentation at the 62nd EASD Annual Meeting, a board proposal to authorize a buyback of up to 10% of issued H shares pending shareholder approval on June 24, and the inclusion of its core product in the national medical insurance reference drug pre-communication supplementary list, strengthening reimbursement access expectations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141451062","isCrawlerRequest":true}